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Abstract
Aim Gestational diabetes (GDM) and mental disorder are common perinatal morbidities and are associated with
adverse maternal and child outcomes. While there is a relationship between type 2 diabetes and mental disorder, the
relationship between GDM and mental disorder has been less studied. We conducted a systematic review and meta-
analysis of the prevalence of mental disorders in women with GDM and their risk for mental disorders compared with
women without GDM.
Methods Published, peer-reviewed literature measuring prevalence and/or odds of GDM and perinatal mental
disorders was reviewed systematically. Risk of bias was assessed using a checklist. Two independent reviewers were
involved. Analyses were grouped by stage of peripartum, i.e. antepartum at the time of GDM diagnosis and after
diagnosis, and in the postpartum.
Results Sixty-two studies were included. There was an increased risk of depressive symptoms in the antenatal period
around the time of diagnosis of GDM [odds ratio (OR) 2.08; 95% confidence interval (CI) 1.42, 3.05] and in the
postnatal period (OR 1.59; 95% CI 1.26, 2.00).
Conclusions Given the potential relationship between GDM and perinatal mental disorders, integration of physical and
mental healthcare in women experiencing GDM and mental disorders could improve short- and long-term outcomes for
women and their children.
Diabet. Med. 00, 1–21 (2019)
Introduction
Gestational diabetes (GDM) is defined as ‘glucose intoler-
ance with onset during pregnancy’. Its global prevalence is
between 5% and 10%, which varies depending on the
diagnostic criteria employed and the population studied. The
prevalence is increasing, mirroring general upward trends in
non-communicable disease and obesity prevalence. GDM is
associated with adverse outcomes for mother and baby,
including obstetric complications such as emergency Cae-
sarean delivery and longer-term risks of subsequent type 2
diabetes in mothers [1]. In children, there may be increased
risk of metabolic syndrome later in life [1] and adverse
neuro-behavioural outcomes, for example hyperactivity and
lower verbal IQ scores [2].
Mental disorder is the most common morbidity of the
peripartum (during pregnancy and up to 1 year following
delivery), with one in five women developing a mental
disorder during pregnancy or in the year following birth [3].
It is also associated with adverse maternal and fetal
outcomes, and emotional and behavioural problems in the
child [4].
There is a growing body of literature suggesting a
bidirectional relationship between type 2 diabetes and
mental disorder, particularly depression. A range of mech-
anisms has been studied, such as inflammation and hypotha-
lamic–pituitary–adrenal axis dysregulation, and shared
socio-environmental risk factors such as obesity and
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deprivation [5]. Given that there is pathophysiology common
to both GDM and type 2 diabetes, i.e. insulin resistance,
there may be a hypothesized association between GDM and
mental disorder.
As with the type 2 diabetes literature, most research on
GDM and mental disorders to date has focused on depres-
sion, either in the postpartum (up to 1 year) following GDM
or cross-sectional associations in the antepartum [6–8]. A
recent review focused only on studies relating to postnatal
depression [9].
The aim of this study was to conduct a systematic review
and meta-analysis of the prevalence of a wider range of
mental disorders than investigated in previous reviews in
women with GDM and their risk for subsequent mental
disorder in the peripartum compared with women without
GDM. Greater understanding of the risk for perinatal mental
disorder in women with GDM could help to provide more
tailored support to these women.
Methods
The review followed Meta-Analyses and Systematic Reviews
of Observational Studies (MOOSE) [10] and Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [11]. It was registered with PROS-
PERO (CRD42016041677).
Data sources
Medline, PsycINFO, EMBASE and CINAHL were
searched separately from inception until 25 April 2019.
Cochrane Library and ClinicalTrials.gov were also
searched using the same period. Search terms used for
Medline, PsycINFO, EMBASE, CINAHL and Cochrane
Library were adapted from previous systematic reviews in
the area [12,13] and Cochrane specialized registers
[14,15] (Appendix S1). Forward and backward citation
tracking was also undertaken.
Study selection
Inclusion criteria were: published, peer-reviewed observa-
tional and intervention studies in any language, measuring
GDM and perinatal mental disorder occurring in the same
pregnancy. In intervention studies, only baseline measure-
ments of mental health were eligible (as opposed to follow-
up data). Perinatal mental disorder was defined as antenatal
(between conception and delivery) or postpartum (up to 1
year following delivery) mood, anxiety, psychotic or eating
disorders, as there were plausible mechanisms for an asso-
ciation between these disorders and GDM. Mental disorder
could be measured either by medical records or diagnostic
and screening measures.
Exclusion criteria were: studies classifying mental disorder
based solely on medication status due to the risk of
misclassification bias when psychotropic prescriptions alone
are used to identify mental disorder [16]. Studies which did
not provide data separately for antenatal and postnatal
periods were ineligible, as hypothesized mechanisms of
association, are potentially different for the antepartum
and postpartum. Studies were also ineligible if mental
disorder was known to have been measured prior to the
onset of GDM: either pre-pregnancy or in early pregnancy.
In studies where mental disorder was clearly measured
during pregnancy but there was uncertainty about when in
pregnancy the mental disorder was measured, these studies
were included in the review but excluded from meta-analysis.
In studies where there was uncertainty about pre-gestational
diabetes (type 1 and type 2 diabetes) being excluded from the
control (non GDM) population, only prevalence data were
used for meta-analysis.
Following de-duplication, titles and abstracts were
screened, followed by full text screening by two independent
reviewers. Sixty-two studies met the inclusion criteria (Fig. 1)
(see Appendix S2 for a list of the studies).
Data extraction
Data extraction was conducted by two independent review-
ers and included study characteristics such as study location,
design and sample size, measurement of GDM and mental
disorder, and inclusion and exclusion criteria. Prevalence and
odds ratios (ORs) and any information on potential mech-
anisms were also extracted. Three of the included papers
required translation to English. The authors of 41 stud-
ies were e-mailed at the data extraction stage to request raw
data or clarify an aspect of their methods. Following a
second e-mail reminder, replies were received from 17. Raw
data were provided by four.
Risk of bias assessment
A component approach to assessment of risk of bias was
employed, as per current PRISMA guidelines [11]. A
What’s new?
• Type 2 diabetes is associated with an increased risk of
mental disorder, particularly depression.
• There is some emerging evidence that gestational
diabetes (GDM) may also be associated with mental
disorder, particularly postnatal depression.
• GDM is associated with an increased risk of both
antenatal and postnatal depressive symptoms, with the
highest risk around the time of GDM diagnosis.
• All healthcare professionals working with women with
GDM should be aware of this increased risk for mental
disorder because effective treatment of the disorder
could improve outcomes for women and their children.
2
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Gestational diabetes and perinatal mental disorder  C. Wilson et al.
Records identified through 
database searches on 29
January  2018: 
CINAHL = 237 
Medline = 288 
EMBASE = 603 
PsycINFO = 93 
Cochrane = 100 
n = 1321 
Additional records identified 
through other sources: 
Forward and backward citation 
tracking (of n=54 plus reviews) 
= 11 
Database update alerts since  
29 January 2018 = 19 
Clinicaltrials.gov = 0 
n = 20 
Titles and abstracts screened after duplicates 
removed: n =  968 
Full text articles assessed for 
eligibility:
n = 332 
Full text articles excluded: 
n = 270 
Reasons for exclusion: 
Abstract (either confirmed unpublished or no 
response to two emails to ask if published) = 29 
Case study = 1 
Data presented elsewhere = 48 
Paper unsuitable in the absence of additional 
data (no response to two emails or unable to 
share data) = 34 
Dissertation or textbook chapter = 4 
Review or commentary = 47 
No measure of GDM = 9 
No measure of maternal mental disorder = 57  
Intervention study with lack of baseline data =
17 
Mental disorders occurring outside the perinatal 
period or prior to GDM diagnosis = 21 
Special population (e.g. preterm labour) = 3 Studies included in 
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FIGURE 1 Flow diagram of study selection.
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modified Newcastle–Ottawa Scale [17] (piloted prior to use)
was used (Table S1) by two independent reviewers. Of most
interest were measurement and selection biases and the
inclusion of significant confounders as most of the studies
were anticipated to be of observational design and these
sources of bias are most likely to impact on the results of an
observational study. Each item was assigned a score from
zero (high risk of bias) to two (low risk of bias). Selection
bias was scored via an assessment of: (1) sample represen-
tativeness and (2) participation rates. Measurement bias was
scored via an assessment of: (1) measure of GDM and (2)
measure of mental disorder. A study with a score of zero in
any of these four elements or on the element of inclusion of
confounders in the design or analysis was deemed at high risk
of bias. Otherwise studies were deemed at low to moderate
risk.
Data synthesis
Studies were grouped by mental disorder and timings of
exposure, i.e. symptoms measured during the antepartum
(cross-sectionally at the time of GDM diagnosis and after
diagnosis) and symptoms measured during the postpartum.
Some papers presented only prevalence data. In such cases,
ORs were calculated from this data (or raw data provided
by authors). If ORs for at least five studies were available
for each disorder at each period, meta-analysis was
undertaken [18]. If there was any doubt as to whether
or not pregestational diabetes had been excluded from the
comparison group without GDM, the ORs for these
studies were not included in the meta-analysis. Figure 2
provides an overview of how the results of the 62 studies
are presented.
Data were analysed using Stata 15. Metan and metaprop
commands were used to produce pooled unadjusted ORs and
prevalence and 95% confidence intervals (CIs) displayed as
forest plots. If at least five adjusted ORs had been available,
meta-analysis would have been repeated using these esti-
mates but this was not available. DerSimonian-Laird random
effects meta-analysis [19] was used because there was
expected to be a degree of heterogeneity between studies
[20,21]. Heterogeneity was assessed using I2, the proportion
of total variation in study estimates that is due to hetero-
geneity [22]. It was decided a priori that I2 > 90% would
preclude meta-analysis as this represents considerable hetero-
geneity [23]. Some of the prevalence meta-analyses produced
I2 > 90%; in these circumstances prevalence is presented as
median with interquartile range (IQR) as a standard
summary measure of non-parametric data. Sensitivity anal-
yses on effect of risk of bias and screening tools vs. diagnostic
codes as measures of mental disorder were conducted when
sufficient studies were available. Cumulative meta-analysis
was used in a leave one out approach using the metacum
command to investigate the impact of sample size on the final
pooled effect estimate.
Publication bias was assessed using funnel plots for meta-
analyses with at least 10 studies using metafunnel command
to assess association between study size and effect size [24].
These were examined for evidence of asymmetry via visual
inspection and Egger’s test for small study effects (metabias
command) [25].
Results
Study characteristics
An overview of study characteristics for all 62 included
papers is provided in Table 1. Fuller descriptions of the study
characteristics are available in Tables S2 and S3. Meta-
analyses were conducted only for studies measuring depres-
sion as there were insufficient studies for other mental
disorders; narrative syntheses are presented for anxiety
disorders, although some of the studies measured both
depression and anxiety symptoms. Although other mental
disorders such as psychotic and eating disorders were
included in the search, only studies measuring anxiety and
depression met selection criteria due to the exclusion of
studies in which mental disorder started prior to the
diagnosis of GDM.
Over half of the studies (N = 38) measured depression
with screening tools, with some studies measuring depression
at more than one time. The most frequently used tool was the
Edinburgh Postnatal Depression Scale (EPDS; N = 16), with
different cut-off scores to indicate ‘caseness’ for depression,
reflecting different populations. Five of the included studies
also used the State–Trait Anxiety Inventory (STAI) as a
measure of anxiety. When diagnostic codes were used, these
were usually International Classification of Diseases, ninth or
tenth revision (ICD-9 or ICD-10).
Many of the studies did not provide clear criteria for GDM
diagnosis. Ten did not provide any information, eight were
self-report and 16, although appearing to use clinical
diagnoses, did not specify diagnostic criteria. Twenty-eight
studies did provide this information. Eight used Carpenter–
Coustan criteria for 100 g 3-h oral glucose tolerance test
(OGTT). For studies using 2-h 75 g OGTT, seven of the
studies used current International Association of Diabetes
and Pregnancy Study Groups (IADPSG) criteria, two used
Australasian Diabetes in Pregnancy Society (ADIPS) criteria
and one used 2008 Canadian Diabetes Association criteria.
One study used Dutch midwifery and obstetric guidelines
and another used Finnish clinical guidelines. Five studies
provided specific diagnostic criteria: the origins of which
were unclear and three merely reported ‘OGTT’.
Twenty-four studies were from North America, 16 from
Europe, 15 from Asia, four from Australasia, two from South
America and one from Africa. Thirteen were upper- or
lower–middle income countries; none were low-income
countries (according to World Bank classification at June
2018). There were no studies from the UK. The most
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Studies providing data for calculation 
of prevalence or odds
See Table S2
Studies that measure GDM and mental disorder but do 
not allow for calculation of prevalence or odds
Antenatal depression = 5
Postnatal depression = 4
Antenatal anxiety = 6
Postnatal anxiety = 2
See Table S3
Depression Anxiety 
disorders
Antenatal any 
time in
pregnancy or 
around time of 
GDM diagnosis
= 3
Postnatal = 3
Antenatal any 
time in
pregnancy or 
around time of 
GDM diagnosis
Antenatal following GDM 
diagnosis
Meta-analysis OR and 
prevalence = 6
Meta-analysis OR only = 0
Meta-analysis prevalence only
= 2
No meta-analysis = 0 
Postnatal
Meta-analysis OR and 
prevalence = 13
Meta-analysis OR 
only = 2
Meta-analysis 
prevalence only = 12
No meta-analysis = 3 
(unclear if pre-GDM 
excluded) 
Antenatal around time of GDM 
diagnosis
Meta-analysis OR and prevalence
= 6
Meta-analysis OR only = 0
Meta-analysis prevalence only = 4
No meta-analysis = 0
Unclear stage of antepartum 
(no meta-analysis)
OR and prevalence = 5
OR only = 3
Prevalence only = 4
62 included studies
Some studies included in more than one category
FIGURE 2 Flow diagram of how data from the 62 studies are presented.
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common study design was a prospective cohort (28 studies).
Eighteen studies were cross-sectional in design, eight were
retrospective cohorts, five were intervention studies and three
were case–control studies. Thirty-six studies were assessed as
high risk of bias; this was predominantly due to lack of
information about how GDM or mental disorder was
diagnosed, increasing the risk of measurement bias and/or
lack of information about participation rates, exclusion or
inclusion criteria preventing accurate assessment of risk of
selection bias.
Odds and prevalence of high levels of antenatal depressive
symptoms in women with GDM around the time of GDM
diagnosis
Twenty-seven studies measured levels of depressive symp-
toms occurring at the time of GDM diagnosis or which were
unclear about when in pregnancy diagnosis of mental
disorder occurred.
Ten studies provided prevalence data at the time of GDM
diagnosis (Table 2) but heterogeneity was 97%, precluding
meta-analysis. Median prevalence of high levels of antenatal
depressive symptoms in women with GDM was 28% (IQR
20%–46%) (10 studies; N = 5515). Six of these studies
(N = 4387) were also used in a meta-analysis of unadjusted
OR (although age-adjusted OR was used for one of the
studies as unadjusted was not provided), yielding a pooled
OR of 2.08 (95% CI 1.42, 3.05) with heterogeneity at 47%
(Fig. 3).
Of the 17 studies not included in meta-analysis (Tables S2
and S3), there were 11 for which the time of depression
measurement in the antepartum in relation to GDM
diagnosis could not be ascertained (references 18, 20, 23,
27, 30, 35, 40, 46, 49, 51 and 60 in Appendix S2). One study
provided only results stratified by BMI (reference 59 in
Appendix S2) and another used depression as exposure not
outcome (reference 53 in Appendix S2). Finally, four studies
presented only mean scores on depression screening tools;
they did not provide data on numbers scoring above and
below a specified cut-off for ‘caseness’ on these tools,
preventing calculation of prevalence or odds (references 15,
22, 37 and 39 in Appendix S2).
Table 1 Characteristics of included studies
Antenatal depression Postnatal depression Antenatal anxiety Postnatal anxiety
Total number 34 34 9 5
Mental disorder measure N (%)
Diagnoses 4 (12) 9 (26) 1 (11) 3 (60)
Screening tools (total) 29 (85) 22 (65) 8 (89) 1 (20)
EPDS 10 14 0 0
BDI 5 1 0 0
CES-D 4 4 0 0
PHQ-9 4 2 0 0
DASS 2 0 2 0
MHI-5 1 0 0 0
MADRS 1 1 0 0
Kessler 6 1 0 0 0
Zung SDS 1 0 0 0
STAI 0 0 5 1
Taylor Anxiety 0 0 1 0
Self report 1 (3) 3 (9) 0 (0) 1 (20)
Sample size N (%)
< 100 7 (21) 4 (12) 1 (11) 0 (0)
100–500 13 (38) 4 (12) 8 (89) 1 (20)
> 500 14 (41) 26 (76) 0 (0) 4 (80)
Study design N (%)
Cross-sectional 13 (38) 3 (9) 4 (44) 0 (0)
Case–control study 2 (6) 2 (6) 0 (0) 0 (0)
Intervention study 2 (6) 2 (6) 2 (23) 0 (0)
Prospective cohort 15 (44) 20 (59) 3 (33) 3 (60)
Retrospective cohort 2 (6) 7 (20) 0 (0) 2 (40)
Location N (%)
Africa 1 (3) 0 (0) 0 (0) 0 (0)
Asia 9 (26) 8 (24) 3 (33) 0 (0)
Australasia 3 (9) 1 (3) 2 (23) 1 (20)
Europe 8 (24) 10 (29) 3 (33) 1 (20)
North America 11 (32) 15 (44) 1 (11) 3 (60)
South America 2 (6) 0 (0) 0 (0) 0 (0)
EPDS, Edinburgh Postnatal Depression Scale; BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies-Depression;
PHQ-9, Patient Health Questionnaire-9; DASS, Depression Anxiety Stress Scales; MHI-5, Mental Health Inventory-5; MADRS,
Montgomery–Asberg Depression Rating Scale; Kessler 6, Kessler 6 Mental Health Scale; Zung SDS, Zung Self-Rating Depression Scale;
STAI, State–Trait Anxiety Inventory.
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Odds and prevalence of high levels of antenatal depressive
symptoms in women with GDM following GDM diagnosis
Eight studies (N = 862) measured levels of depressive symp-
toms occurring in the late antepartum following GDM
diagnosis (Table 3). Pooled prevalence for high levels of
depressive symptoms across all studies was 26% (95% CI
18%, 35%) with heterogeneity at 66%.
Six studies (N = 788) provided data on unadjusted ORs
for high levels of depressive symptoms in those who received
and did not receive the GDM diagnosis. Pooled unadjusted
OR was 1.41 (95% CI 0.88, 2.25), with heterogeneity at
23% (Fig. 4).
Odds and prevalence of high levels of postnatal depressive
symptoms in women with GDM
Thirty-four studies measured depression as a diagnosis or
levels of depressive symptoms occurring in the postpartum.
Twenty-five studies (N = 2 324 634) provided prevalence
data (Table 4). Heterogeneity on meta-analysis was 99% so
median prevalence of high levels of postnatal depressive
symptoms in women with GDM is presented, which was
13% (IQR 10%–26%).
Thirteen studies provided unadjusted ORs for high levels
of postnatal depressive symptoms in women with GDM vs.
those without GDM. Two further studies provided age-
adjusted estimates which were used as an unadjusted
estimate was unavailable (Table 4). Pooled OR for these
15 studies (N = 1 059 703) was 1.59 (95% CI 1.26, 2.00),
with heterogeneity at 79% (Fig. 5).
On visual inspection of the funnel plot including studies in
the meta-analysis of ORs, there was some possible asymme-
try, with some missing studies in the bottom left corner
(Fig. 6) and Egger’s test suggested a significant small study
effect (P = 0.003).
Seven studies were not included in the meta-analysis
because they presented only incidence data (references 6, 42
and 49 in Appendix S2), continuous EPDS scores (reference
39 in Appendix S2) or ORs that could not be used as it was
unclear whether pregestational diabetes had been excluded
from the control population and from which prevalence
could not be calculated (references 1, 38 and 56 in
Appendix S2; see also Tables S2 and S3).
Sensitivity analyses
Studies at high risk of bias were removed in the postnatal
meta-analysis (Table 5) but there were insufficient studies
with low to moderate risk of bias in the antenatal subgroups
to facilitate this. This gave median prevalence (12 studies;
N =1 970 534) of 13% (IQR 11%–16%) and pooled OR
(seven studies; N = 351 854) of 1.27 (95% CI 1.02, 1.57)
with heterogeneity at 72%. Another sensitivity analysis in
the postpartum removed six studies (references 3, 14, 54, 58,
61 and 62 in Appendix S2) that used diagnostic as opposed
to screening measures. This gave median prevalence (20
studies; N = 26 541) of 14% (IQR 12%–31%) and pooled
OR (10 studies; N = 11 852) of 1.75 (95% CI 1.29, 2.37)
with heterogeneity at 57%. In the antenatal meta-analyses,
there were no studies that utilized diagnostic tools at the time
of GDM diagnosis or following it. Cumulative meta-analysis
FIGURE 3 Forest plot showing pooled odds ratios for high levels of antenatal depressive symptoms at the time of GDM diagnosis in women with
GDM vs. those without GDM.
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assessing the impact of study sample size on pooled ORs in
each of the three meta-analyses suggested no significant
impact of larger studies (Fig. S1).
Anxiety symptoms and disorders
Three studies provided data on the prevalence or odds of
high levels of anxiety symptoms or anxiety disorders at any
time during pregnancy or around the time of GDM diagno-
sis, and three in the postpartum. These results are summa-
rized in Table 5.
There were a further five studies in which STAI was used
and one in which the Depression Anxiety Stress Scales
(DASS) was used (reference 22 in Appendix S2); data were
presented as continuous scores, precluding calculation of
odds or prevalence (Table S3). Four studies utilized the STAI
at any time during pregnancy or around the time of GDM
diagnosis (references 12, 17, 37 and 43 in Appendix S2).
Two of these studies of around 100 women examined
differences in STAI state anxiety scores around the time of
GDM diagnosis between those with and without GDM; one
found significantly higher scores in GDM (reference 17 in
Appendix S2) and the other did not (reference 37 in
Appendix S2). The study with statistically significant differ-
ences followed up women in the late antepartum and
postpartum but found no significant differences between
women with and without GDM at these points in the
peripartum (reference 17 in Appendix S2). Another study
post GDM diagnosis also found no significant differences
(reference 42 in Appendix S2). However, a Danish popula-
tion-based cohort found a statistically significant incidence
rate ratio for postpartum reactions to severe stress (ICD-10)
in GDM of 1.42 (95% CI 1.03, 1.97) (reference 52 in
Appendix S2).
Discussion
Main findings
This is the first study that has meta-analysed data from
studies examining a range of mental disorders throughout the
peripartum. We found that the prevalence of high levels of
depressive symptoms around the time of GDM diagnosis was
28% (pooled OR 2.08) and following diagnosis was 26%
(pooled OR 1.41). This is higher than that expected in the
general pregnant population [26,27]. In the postpartum, the
prevalence of depression in women diagnosed with GDM
during pregnancy was 13% (pooled OR 1.59). This is similar
to a recent meta-analysis which found a pooled relative risk
for postnatal depression in women with GDM of 1.59 [9].
However, the studies included in the two reviews differ
slightly, due to stricter inclusion and exclusion criteria in our
review, such as ensuring the exclusion of pregestational
diabetes from control groups and also a more recent
literature search in our study.
It is surprising that there were not more studies that
measured levels of anxiety, although there was some
evidence for significantly higher anxiety scores in women at
the time of GDM diagnosis but no evidence for an increase in
anxiety following diagnosis in the antepartum (albeit only
two studies identified). There was some evidence for
increased odds of postnatal anxiety in women with GDM.
Moreover, there is clearly a significant degree of comorbidity
between anxiety and depression, and indeed, most of the
FIGURE 4 Forest plot showing pooled odds ratios for high levels of antenatal depressive symptoms in women after a diagnosis of GDM vs. those
without a diagnosis of GDM.
ª 2019 The Authors.
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studies that measured both depression and anxiety generally
yielded consistent findings between both disorders, whether
it be an increased risk for both in the antepartum (reference
26 in Appendix S2) or postpartum (reference 3 in
Appendix S2) or no evidence for an increased risk for either
depression or anxiety in the antepartum (reference 18 in
Appendix S2) or postpartum (reference 19 in Appendix S2).
Potential mechanisms
The potential mechanisms underlying the link between GDM
and mental disorders are unknown. The type 2 diabetes
literature describes potential biological and psychosocial risk
factors. Cytokines, part of the inflammatory response, are
raised in both depression and type 2 diabetes [28] and can
cause pancreatic b-cell destruction, leading to insulin resis-
tance. There is now growing evidence supporting an inflam-
matory process in individuals with perinatal depression [29].
Cytokines also activate the hypothalamic–pituitary–adrenal
axis which regulates the body’s response to stress. There may
also be an increased risk of hypothyroidism in GDM, which
is known to be associated with depression [30].
Psychological factors include the burden of managing a
medical condition during pregnancy, which may increase the
risk of developing a perinatal mental disorder. Qualitative
research exploring women’s experiences of GDM has high-
lighted the strong but widely differing emotional responses to
the diagnosis including shock, tearfulness and guilt. Major
changes to lifestyle may also be required including dietary
changes and blood glucose monitoring [31].
Strengths and limitations
This review provides a comprehensive synthesis of the
literature to date on the association between GDM and
mental disorders following diagnosis of GDM. That analyses
were grouped by stage of the peripartum is a particular
strength of this review because symptoms of mental disorder
may fluctuate throughout the peripartum [32]. Significant
efforts were made to obtain raw data for the meta-analysis.
Assessment of risk of bias allowed the influence of this on the
results of meta-analysis to be considered within sensitivity
FIGURE 5 Forest plot showing pooled odds ratios for high levels of postnatal depressive symptoms in women with GDM vs. those without GDM.
FIGURE 6 Funnel plot of association between study size and effect size
in those studies used in meta-analysis of odds ratios for postnatal
depression.
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analysis. Over half of the 62 studies were assessed as at high
risk of bias.
Removal of studies at high risk of bias from the postnatal
meta-analyses reduced the effect estimates and there was also
some evidence of small study bias. One of the potential
sources of bias was measurement bias. All of the mental
disorder screening tools used were validated but only
indicate ‘caseness’ for mental disorder; they are not diagnos-
tic. There is also little consensus on optimal cut-off scores for
most of the tools. Thus, it is perhaps unsurprising that effect
estimates increased when studies using diagnostic codes were
removed in sensitivity analyses. However, it is also notewor-
thy that all three studies contributing to the postnatal meta-
analysis that used diagnostic codes for depression (that also
had sample sizes > 10 000) gave ORs that were statistically
significant, albeit one was of borderline significance (refer-
ences 7, 54 and 58 in Appendix S2).
There is also substantial heterogeneity in how GDM is
defined (see tables). Unfortunately, many of the studies did
not report this. There is some evidence for a relationship
between blood glucose below diagnostic threshold for GDM
and depression and anxiety [33]. Indeed, since the seminal
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO)
study observed a linear relationship between elevated
maternal glucose concentrations below that of overt diabetes
and adverse outcomes, many have argued that GDM should
be conceptualized as a continuum of dysglycaemia [34].
Recognizing the heterogeneity of GDM, authors of studies in
which it seemed likely that results of GDM testing may be
available were asked if they would be willing to provide this
raw data. However, only two authors felt able to share,
precluding any meaningful analysis.
However, management of GDM with insulin may be an
indicator of its severity and four of the included studies
compared risk for depression between different treatment
modalities. Two found no difference in risk for antenatal
depression between women managing their GDM with or
without insulin (references 15 and 16 in Appendix S2),
whereas another study did find an increased risk for
postnatal depression in women using insulin (reference 45
in Appendix S2) but another study in the postpartum did not
(reference 47 in Appendix S2). Clearly an alternative
mechanism for any potential increased risk beyond insulin
use being a marker of GDM severity is that its injection
merely represents an additional stressor for women.
Further limitations relate to unmeasured confounding in
the included studies. As most of the studies were observa-
tional, there are a number of important confounders which
could limit causal inference. Most studies provided only
unadjusted estimates; estimates adjusted for important con-
founders were limited. A key confounder when considering
the direction of relationships is early pregnancy or pre-
pregnancy mental disorder and use of psychotropic medica-
tion; timing of mental disorder measurement may not
capture timing of onset. A few studies excluded mental
disorder prior to pregnancy and five adjusted for pre-
pregnancy mental disorder, which led to significant attenu-
ation of results in two studies (references 51 and 61 in
Appendix S2). Another confounder is obesity [1,12]. The
intention was to conduct subgroup analyses by BMI but
while a number of studies provided data on BMI distribution
(see tables), insufficient data on effect estimates by BMI were
available to facilitate this. Adjustment for BMI reduced effect
estimates in one study (reference 58 in Appendix S2) but not
in others (references 36, 53 and 59 in Appendix S2). There
may also be ethnic differences in risk for GDM [35] and
mental disorder [36]. While a number of included studies
reported the ethnicity of their population (see tables), only
two studies in the meta-analyses provided ethnicity adjusted
ORs (references 29 and 36 in Appendix S2) and two stratified
by ethnicity (references 38 and 58 in Appendix S2). Finally,
this review only considers the risk for mental disorders
following GDM. Future reviews would usefully examine the
risk for GDM in women with mental disorders, particularly
given some (albeit limited) emerging evidence for an
increased risk of GDM in those using antipsychotics [37,38].
Implications
There are a number of examples of effective integration of both
physical and mental healthcare, including in the type 2
diabetes population [39]. All healthcare professionals in
contact with women with GDM, from diabetologists, to
obstetricians, to midwives and health visitors, could ask about
mental health during contacts with health services in the
perinatal period.CurrentUKNational Institute forHealth and
Care Excellence (NICE) guidelines suggest that professionals
consider asking all women two questions about lowmood and
loss of interest (the Whooley questions) as part of a general
discussion about thewoman’swellbeing in the antepartumand
postpartum [27]. Moreover, recent US recommendations on
screening for perinatal depression have recommended asking
women not only about depressive symptoms, but also about
associated risk factors [40]. The results of our review suggest
that GDM may be considered one of these risk factors,
emphasizing the importance of this enquiry at every contact
and that women with GDM may require additional support
during pregnancy and in the postpartum. This may involve
liaison with primary care or psychiatry services.
There may be a perception that women with mental
disorder may be less likely to engage with support offered,
whether it be for physical or mental health. However, in a
recent randomized controlled trial of an intervention in obese
pregnant women to reduce gestational weight gain, depres-
sion was not associated with poorer adherence [41]. More-
over, recognition and treatment of mental disorder in women
with GDM may lead to improved outcomes. In type 2
diabetes, there is some evidence that treatment of depression
is associated with improved glycaemic control [42] and in
GDM, a cross-sectional relationship has been observed
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between levels of depressive symptoms and glycaemic control
[43] and compliance with GDM therapy [44]. Severity of
hyperglycaemia during pregnancy may influence future risk
of type 2 diabetes in the mother and risk of metabolic
syndrome [1] and adverse neurobehavioural outcomes in the
child [2]. Thus, the potential benefits of providing mental
healthcare to women with GDM are numerous and far-
reaching.
In conclusion, this systematic review and meta-analysis
found an increased risk of probable antenatal and postnatal
depression (and possibly anxiety) in women with GDM.
Future research would usefully focus on risk for other mental
disorders, including those occurring prior to pregnancy and
in early pregnancy prior to the onset of GDM, and on
exploring possible mechanisms.
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